ArticleMethodsX2023
Insulin secretion assays in an engineered MIN6 cell line.
Article in MethodsX, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Light-activated tetanus neurotoxin for conditional proteolysis and inducible synaptic inhibition in vivo.Nature methods · 2026Article
- Metabolic STAMP for deciphering GPCR-regulated insulin secretion by pancreatic β cells.bioRxiv : the preprint server for biology · 2025Article
- Phase separation of a PKA type I regulatory subunit regulates β-cell function through cAMP compartmentalization.PLoS biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Insulin secretion from pancreatic beta cells is crucial for maintaining glucose homeostasis. The murine insulinoma derived MIN6 cell line is commonly used as a model for insulin secretion studies. However, its glucose responsiveness wanes with passaging, and insulin secretion is traditionally measured by expensive and time-consuming RIA or ELISA. We have developed a MIN6 subclone (MIN6-6) that allows for high throughput assay of insulin secretion in both population and single cells. In addition, MIN6-6 also expresses Cas9, permitting genome wide CRISPR screen of insulin secretion using a pooled sgRNA library. Here we provide methods for assaying insulin secretion both in bulk and in single cells in MIN6-6 cells, as well as for CRISPR screen of insulin secretion.•A highly glucose responsive beta cell reporter line (MIN6-6) with multiple engineered functionalities.•Allows for CRISPR/Cas9 mutagenesis, quantification of bulk insulin secretion by a straightforward nanoLuc assay and visualization of intracellular insulin granules.•Allows for en masse quantification of insulin granule exocytosis in individual cells under multiple conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.